Mednet Logo

How would you boost a high-risk prostate cancer patient who received standard fractionation treatment and is not able to get LDR boost given COVID-19?

Would you use SBRT, hypofractionated or standard fractionated boost?
3 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Virginia Commonwealth University Medical Center
Answered on

I will assume for the sake of argument that he is also getting ADT as part of his treatment.

If he has responded well to ADT (I like to see about a 90% drop in the PSA within 3 months), my preference would be to try to delay until it's reasonable from an infectious disease perspective to proceed wit...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · UPMC Hillman Cancer Center
Answered on

The question posed is clinically relevant and asks us to weigh the optimal treatment for a high risk patient in the current pandemic setting. I presume the initial course of radiotherapy was standard fractionation of 45 Gy in 25 fractions. Boosting the primary would be standard of care and supported...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · CoxHealth Radiation Oncology
Answered on

We are currently going through extraordinary circumstances which would require unique interventions and approaches.

Most high risk patients prostate cancer patients should already be on androgen deprivation. Hence, delaying the seed implant a few weeks or even months until we address our PPE shortag...

Join for free or sign in to see the full answer